Jie Chen
Jie Chen
Publications
HideReprogramming the Intrahepatic Cholangiocarcinoma Immune Microenvironment by Chemotherapy and CTLA-4 Blockade Enhances Anti-PD1 Therapy.
Cancer Immunol Res. 2024;12(4):400-412 - PMID: 38260999 - PMCID: PMC10985468 - DOI: 10.1158/2326-6066.CIR-23-0486
Reprogramming Intrahepatic Cholangiocarcinoma Immune Microenvironment by Chemotherapy and CTLA-4 Blockade Enhances Anti-PD1 Therapy.
Losartan prevents tumor-induced hearing loss and augments radiation efficacy in NF2 schwannoma rodent models.
Sci Transl Med. 2021;13(602):ePub - PMID: 34261799 - PMCID: PMC8409338 - DOI: 10.1126/scitranslmed.abd4816
Antibody-mediated delivery of viral epitopes to tumors harnesses CMV-specific T cells for cancer therapy.
Nat Biotechnol. 2020;38(4):420-425 - PMID: 32042168 - PMCID: PMC7456461 - DOI: 10.1038/s41587-019-0404-8
Overcoming sorafenib treatment-resistance in hepatocellular carcinoma: A future perspective at a time of rapidly changing treatment paradigms.
EBioMedicine. 2020;52:102644 - PMID: 32014823 - PMCID: PMC6997488 - DOI: 10.1016/j.ebiom.2020.102644
A cerebellopontine angle mouse model for the investigation of tumor biology, hearing, and neurological function in NF2-related vestibular schwannoma.
Nat Protoc. 2019;14(2):541-555 - PMID: 30617350 - PMCID: PMC6571021 - DOI: 10.1038/s41596-018-0105-7
Targeting the cMET pathway augments radiation response without adverse effect on hearing in NF2 schwannoma models.
Proc Natl Acad Sci U S A. 2018;115(9):E2077-E2084 - PMID: 29440379 - PMCID: PMC5834719 - DOI: 10.1073/pnas.1719966115